Abid Karim, Rochat Bertrand, Lassahn Paul-Gerhard, Stöcklin Reto, Michalet Sophie, Brakch Noureddine, Aubert Jean-Francois, Vatansever Bilgin, Tella Patricia, De Meester Ingrid, Grouzmann Eric
Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland.
J Biol Chem. 2009 Sep 11;284(37):24715-24. doi: 10.1074/jbc.M109.035253. Epub 2009 Jul 20.
There is little information on how neuropeptide Y (NPY) proteolysis by peptidases occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive forms and also because the factors affecting the expression of these enzymes have been poorly studied. In the present study, LC-MS/MS was used to identify and quantify NPY fragments resulting from peptidolytic cleavage of NPY(1-36) upon incubation with human serum. Kinetic studies indicated that NPY(1-36) is rapidly cleaved in serum into 3 main fragments with the following order of efficacy: NPY(3-36) >> NPY(3-35) > NPY(2-36). Trace amounts of additional NPY forms were identified by accurate mass spectrometry. Specific inhibitors of dipeptidyl peptidase IV, kallikrein, and aminopeptidase P prevented the production of NPY(3-36), NPY(3-35), and NPY(2-36), respectively. Plasma kallikrein at physiological concentrations converted NPY(3-36) into NPY(3-35). Receptor binding assays revealed that NPY(3-35) is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY(3-35) may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY(3-36).
关于血清中肽酶对神经肽Y(NPY)的蛋白水解过程,目前所知甚少,部分原因是缺乏可靠的技术来区分不同的NPY免疫反应形式,而且对影响这些酶表达的因素也研究不足。在本研究中,采用液相色谱-串联质谱法(LC-MS/MS)来鉴定和定量人血清与NPY(1-36)孵育后肽酶解产生的NPY片段。动力学研究表明,NPY(1-36)在血清中迅速裂解为3个主要片段,裂解效率顺序如下:NPY(3-36) >> NPY(3-35) > NPY(2-36)。通过精确质谱鉴定出痕量的其他NPY形式。二肽基肽酶IV、激肽释放酶和氨肽酶P的特异性抑制剂分别阻止了NPY(3-36)、NPY(3-35)和NPY(2-36)的产生。生理浓度的血浆激肽释放酶将NPY(3-36)转化为NPY(3-35)。受体结合试验表明,NPY(3-35)不能与NPY Y1、Y2和Y5受体结合;因此,NPY(3-35)可能是Y2/Y5激动剂NPY(3-36)的主要代谢清除产物。